Cancer HorizonsAll NewsBlogsCaregivingDiet and ExerciseFinancialPsychosocialRecipesSexual HealthSide EffectSponsoredSurvivorship
All VideosCURE ConnectionsCURE Expert Connections®CURE Speaking OutCURE TVEducated Patient Sound BitesOn Demand: Webinars
Conference Coverage Conference Listing
CURE AdventuresCURE AwardsEducated Patient In Person EducationEducated Patient Virtual Education
Advocacy GroupsArt GalleryClinical Trial CornerHeal®PartnersPodcastsPublicationsShare Your Story
Subscribe
Blood CancersBlood CancersBlood CancersBlood Cancers
Brain Cancer
Breast CancerBreast Cancer
Childhood Cancers
Gastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal Cancers
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancerGynecologic CancerGynecologic Cancer
Head & Neck Cancer
LeukemiaLeukemiaLeukemia
Lung Cancer
LymphomaLymphomaLymphomaLymphoma
Rare CancersRare Cancers
Sarcoma
Skin Cancer/Melanoma
Thyroid Cancer
Spotlight -
  • Blogs
  • Breast Cancer Webinar Series
  • Cancer Horizons
  • Clinical Trial Corner
  • Heal®
  • Publications
  • Videos
Blood CancersBlood CancersBlood CancersBlood Cancers
Brain Cancer
Breast CancerBreast Cancer
Childhood Cancers
Gastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal Cancers
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancerGynecologic CancerGynecologic Cancer
Head & Neck Cancer
LeukemiaLeukemiaLeukemia
Lung Cancer
LymphomaLymphomaLymphomaLymphoma
Rare CancersRare Cancers
Sarcoma
Skin Cancer/Melanoma
Thyroid Cancer
    • Subscribe
Advertisement

Article

May 11, 2011

Navigating through the complex web of clinical trials

Author(s):

Debu Tripathy

Our stories and blogs about new treatments invariably raise questions that pertain to different clinical situations being experienced by our readers. Would this new treatment apply to my condition? How would I get access to this new drug through a clinical trial? The answer is complicated.The determination of who qualifies for an experimental trial, known as "eligibility criteria," can look like a series of roadblocks based on the stage of disease, prior therapies and a long list of blood tests that must return in a certain range. Some of the criteria are becoming even more complex because trials are being designed more from a biological standpoint. In fact, some trials are now addressing a particular gene mutation as opposed to a type of tumor. The rationale for this is that biology may trump the tissue of origin – we are getting more clues every year about specific tumor alterations that make them sensitive or resistant to targeted drugs. Also, genetic testing of tumors has become routine and quick.This trend is also spilling into clinical practice as newer gene and protein tests are becoming commercially available. In some cases, these test are being used "ahead of the data," or in other words, before we have definitive proof that a given treatment indicated by the test is really better that standard treatment. Imagine that a case of breast cancer that has not responded to the usual hormonal and chemotherapeutic drugs is found to express a protein found in gastrointestinal sarcoma tumor (GIST), which responds to the chronic myelogenous leukemia drug Gleevec. There are really no studies to verify that this strategy would work, but it certainly is very appealing. According to most guidelines, there are very few genetic tests that are actually "approved" as being proven to help with treatment decisions. Even BRCA testing for the breast and ovarian cancer susceptibility gene is not currently used to choose drugs in patients with cancer, but it is, of course being used to identify high-risk patients who need enhanced surveillance or even preventive surgery. For clinical trials, however, BRCA testing in patients with cancer is being used for some PARP inhibitor trials based on the biology of these drugs, which appear to inhibit DNA repair. These drugs might be more effective in patients who carry mutations in BRCA, which impairs DNA repair and might therefore predict extreme sensitivity to PARP inhibitors. However, we don't yet know that PARP inhibitors work only in BRCA-deficient cells, so this whole approach is investigational. So how is one in general supposed to navigate the complex web of choosing trials and knowing if one is eligible in the first place? CURE offers some resources to help with clinical trials, and websites are becoming better as search tools, such as www.clinicaltrials.org or www.breastcancertrials.org (specifically for breast cancer). You can search through various clinical trial websites in our Toolbox listing. You can also review our Patient's Guide to Clinical Trials for more information.It is probably not helpful to have unapproved protein or genetic tests performed on your tumor unless it is being done as part of a clinical trial to test for eligibility. However, it is very likely that newer tests will become more widely available and useful in the very near future.

Newsletter

Stay up to date on cancer updates, research and education

Subscribe Now!
Related Videos
Picture of Suleika Jaouad
Picture of Dr. Alexander Spira
Dr. Eric Singhi
Related Content
Advertisement
Illustration of Georgia Hurst
September 9th 2025

Standing Up to Cancer with Lynch Syndrome

Georgia Hurst
The Importance of Spotting Endometrial Cancer
September 9th 2025

The Importance of Spotting Endometrial Cancer

picture of a lung x-ray
September 9th 2025

Rybrevant Plus Lazcluze Associated with Survival Improvement in NSCLC

Alex Biese
ROS1+ Non-Small Cell Lung Cancer: Progress in Care
September 9th 2025

ROS1+ Non-Small Cell Lung Cancer: Progress in Care

illustration of lungs
September 9th 2025

Ivonescimab Plus Chemo Delays NSCLC Progression

Ashley Chan
Portrait of Ronald Chin
September 9th 2025

Standing Up to Cancer on My Own Two Feet

Ronald Chin
Related Content
Advertisement
Illustration of Georgia Hurst
September 9th 2025

Standing Up to Cancer with Lynch Syndrome

Georgia Hurst
The Importance of Spotting Endometrial Cancer
September 9th 2025

The Importance of Spotting Endometrial Cancer

picture of a lung x-ray
September 9th 2025

Rybrevant Plus Lazcluze Associated with Survival Improvement in NSCLC

Alex Biese
ROS1+ Non-Small Cell Lung Cancer: Progress in Care
September 9th 2025

ROS1+ Non-Small Cell Lung Cancer: Progress in Care

illustration of lungs
September 9th 2025

Ivonescimab Plus Chemo Delays NSCLC Progression

Ashley Chan
Portrait of Ronald Chin
September 9th 2025

Standing Up to Cancer on My Own Two Feet

Ronald Chin
About Us
Advertise / Support
Editorial Board
Contact Us
CancerNetwork.com
TargetedOnc.com
OncLive.com
OncNursingNews.com
Terms & Conditions
Privacy
Do Not Sell My Information
Contact Info

259 Prospect Plains Rd, Bldg H,
Monroe, NJ 08831

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.